Syndromes Without a Name Bring Labs an Uphill Battle
In an era when genetic and genomic testing are theoretically affordable and accessible, why do so many patients remain undiagnosed?
In an era when genetic and genomic testing are theoretically affordable and accessible, why do so many patients remain undiagnosed?
Is at-home sample collection the solution to lagging cancer screening uptake—or does this approach introduce a new set of challenges?
Several methods are being developed that improve the ability to rapidly identify organisms and report susceptibility results.
Polygenic risk scores may offer new screening and risk stratification options for cardiovascular disease—but how valuable are they?
Artificial intelligence models have a valuable role to play in each phase of the total testing process.
Genomic epidemiology can provide insights into pathogen transmission and evolution—and facilitate better countermeasures against infectious disease.
Juan Antonio Retamero, MD, shares his thoughts on recent trends in AI and digital pathology, and how they may progress.
Artificial intelligence won’t take your job—but what are the real concerns around healthcare AI and its use?
AI is an increasingly useful tool in pathology—but its full value can only be realized in collaboration with human experts.
Genomic sequencing is almost twice as likely to yield a diagnostic result, but lags behind panel testing in speed, cost, and concordance.
A new five-metabolite blood test designed by algorithm could simplify and speed up this challenging diagnosis.